Oritavancin Activity against Staphylococcus aureus Causing Invasive Infections in U.S. and European Hospitals: a 5-Year International Surveillance Program
Author(s) -
Rodrigo E. Mendes,
Hélio S. Sader,
Robert K. Flamm,
David J. Farrell,
Ronald N. Jones
Publication year - 2014
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02482-13
Subject(s) - daptomycin , staphylococcus aureus , vancomycin , microbiology and biotechnology , methicillin resistant staphylococcus aureus , medicine , biology , bacteria , genetics
In this study, oritavancin had modal MIC, MIC50 , and MIC90 values of 0.03, 0.03, and 0.06 μg/ml, respectively, againstStaphylococcus aureus . Similar results (MIC50/90 , 0.03/0.06 μg/ml) were observed against methicillin-resistant and -susceptible isolates and those demonstrating multidrug-resistant (MDR) and non-MDR phenotypes. When oritavancin (MIC50/90 , 0.06/0.12 mg/ml) was tested againstS. aureus with elevated MIC values for daptomycin (i.e., 1 to 4 mg/ml) and vancomycin (i.e., 2 mg/ml), it showed MIC results 2-fold higher than those for the more susceptible vancomycin or daptomycin counterparts (MIC50/90 , 0.03/0.06 mg/ml), yet it inhibited these isolates at ≤0.25 mg/ml.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom